Reply

Annals of Neurology

Volumn 67, Issue 2, 2010, Pages 270-271

  Bourdette, Dennis ^a   Neuwelt, Edward ^a   Doolittle, Nancy ^a   Kraemer, Dale ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NATALIZUMAB;

CANCER INCIDENCE; DRUG ACTIVITY; EPSTEIN BARR VIRUS; HUMAN; LETTER; MULTIPLE SCLEROSIS; NONHUMAN; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; CENTRAL NERVOUS SYSTEM NEOPLASMS; HUMANS; LYMPHOMA;

EID: 77949407434     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.21954     Document Type: Letter

References (4)

1. Schweikert A, Kremer M, Ringel F, et al. Primary central nervous system lymphoma in a patient treated with natalizumab. Ann Neurol 2009;66:403-406.
2. Bozic C, LaGuette J, Panzara MA, Sandrock AW. Natalizumab and central nervous system lymphoma: no clear association. Ann Neurol 2009;66:261-262.
3. Olson JE, Janney CA, Rao RD, et al. The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis. Cancer 2002;95:1504-1510.
4. Bashir RM, Hochberg FH, Harris NL, Purtilo D. Variable expression of Epstein-Barr virus genome as demonstrated by in situ hybridization in central nervous system lymphomas in immuno-compromised patients. Mod Pathol 1990;3:429-434.